Literature DB >> 19837864

Effects of HMGB1 on in vitro responses of isolated muscle fibers and functional aspects in skeletal muscles of idiopathic inflammatory myopathies.

Cecilia Grundtman1, Joseph Bruton, Takashi Yamada, Therese Ostberg, David S Pisetsky, Helena Erlandsson Harris, Ulf Andersson, Ingrid E Lundberg, Håkan Westerblad.   

Abstract

Idiopathic inflammatory myopathies (IIMs) are heterogeneous rheumatic disorders of unknown cause characterized by muscle weakness, inflammatory cell infiltrates, and major histocompatibility complex (MHC) class I expression on muscle fibers. The nonhistone nuclear protein alarmin high-mobility group box 1 protein (HMGB1) has been detected extranuclearly in muscle biopsies from patients with IIMs. We hypothesize that HMGB1 has a central role in the cause of muscle weakness, particularly in the early phases of IIMs. Experiments were performed on skeletal muscle fibers isolated from adult mice, which were exposed to recombinant interferon (IFN)-gamma or HMGB1. The myoplasmic free [Ca(2+)] was measured. Stimulation with IFN-gamma resulted in increased HMGB1 expression in muscle nuclei and the myoplasm. Exposure to HMGB1 induced a reversible up-regulation of MHC class I in the muscle fibers. However, HMGB1 exposure caused an irreversible decrease in Ca(2+) release from the sarcoplasmic reticulum during fatigue, induced by repeated tetanic contractions. HMGB1 and MHC class I were frequently colocalized in the myoplasm of muscle fibers in muscle biopsies from patients with early IIMs. However, HMGB1-expressing fibers outnumbered fibers expressing MHC class I. Our data indicate that HMGB1 could be an early inducer of skeletal muscle dysfunction in IIMs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19837864     DOI: 10.1096/fj.09-144782

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  33 in total

Review 1.  HMGB1: a multifunctional alarmin driving autoimmune and inflammatory disease.

Authors:  Helena Erlandsson Harris; Ulf Andersson; David S Pisetsky
Journal:  Nat Rev Rheumatol       Date:  2012-01-31       Impact factor: 20.543

Review 2.  Role of Jo-1 in the Immunopathogenesis of the Anti-synthetase Syndrome.

Authors:  Dana P Ascherman
Journal:  Curr Rheumatol Rep       Date:  2015-09       Impact factor: 4.592

3.  [Early symptoms of dermatomyositis and antisynthetase syndrome].

Authors:  B Maurer
Journal:  Z Rheumatol       Date:  2013-12       Impact factor: 1.372

Review 4.  Acute effects of reactive oxygen and nitrogen species on the contractile function of skeletal muscle.

Authors:  Graham D Lamb; Håkan Westerblad
Journal:  J Physiol       Date:  2010-11-01       Impact factor: 5.182

Review 5.  Ventilator-induced diaphragm dysfunction in critical illness.

Authors:  Yung-Yang Liu; Li-Fu Li
Journal:  Exp Biol Med (Maywood)       Date:  2018-11-19

Review 6.  The Immune Response and the Pathogenesis of Idiopathic Inflammatory Myositis: a Critical Review.

Authors:  Angela Ceribelli; Maria De Santis; Natasa Isailovic; M Eric Gershwin; Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 8.667

Review 7.  Causes and consequences of endoplasmic reticulum stress in rheumatic disease.

Authors:  Fatemeh Navid; Robert A Colbert
Journal:  Nat Rev Rheumatol       Date:  2016-12-01       Impact factor: 20.543

Review 8.  Risk factors and disease mechanisms in myositis.

Authors:  Frederick W Miller; Janine A Lamb; Jens Schmidt; Kanneboyina Nagaraju
Journal:  Nat Rev Rheumatol       Date:  2018-04-20       Impact factor: 20.543

Review 9.  Biologic therapy in the idiopathic inflammatory myopathies.

Authors:  Thomas Khoo; Vidya Limaye
Journal:  Rheumatol Int       Date:  2019-11-04       Impact factor: 2.631

10.  HMGB1 expression and muscle regeneration in idiopathic inflammatory myopathies and degenerative joint diseases.

Authors:  Karolina Cseri; János Vincze; Julianna Cseri; János Fodor; Zoltán Csernátony; László Csernoch; Katalin Dankó
Journal:  J Muscle Res Cell Motil       Date:  2015-03-12       Impact factor: 2.698

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.